Fortitude Family Office’s Ligand Pharmaceuticals LGND Stock Holding History

Fortitude Family Office’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.87K	Buy	6 +1	+20%	+$296	﹤0.01%	2048
2026 Q2	$1.58K	Buy	5 +1	+25%	+$236	﹤0.01%	1581
2026 Q1	$799	Buy	4 +3	+300%	+$594	﹤0.01%	1568
2025 Q4	$189	Buy	+1	New	+$192	﹤0.01%	1870

Other funds holding LGND

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return

Woodstock Corp Boston, Massachusetts $1.24B AUM 22.02% 1-Year Est. Return

MNBTD

Moody National Bank Trust Division Galveston, Texas $1.21B AUM 28.25% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

TAM

Tealwood Asset Management Minneapolis, Minnesota $251M AUM 42.58% 1-Year Est. Return

Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return

Equitable Trust Nashville, Tennessee $2.38B AUM 22.38% 1-Year Est. Return

ACM

Argent Capital Management St Louis, Missouri $3.14B AUM 31.36% 1-Year Est. Return

CWC Advisors Lake Oswego, Oregon $215M AUM 18.92% 1-Year Est. Return

Fortitude Family Office's LGND Position: Q3 2026 in Review

Fortitude Family Office increased its Ligand Pharmaceuticals (LGND) stake by 20% in Q3 2026, buying an estimated $296 and bringing the position to 6 shares worth $1.87K. The position accounts for ﹤0.01% of the portfolio, ranked #2048.

Fortitude Family Office first reported a position in LGND in Q4 2025 and has held it in 4 quarters since. 35 funds tracked by Wall St. Rank hold LGND as of Q3 2026.

Fortitude Family Office held 6 shares of Ligand Pharmaceuticals worth $1.87K as of Q3 2026.
Fortitude Family Office bought 1 Ligand Pharmaceuticals share in Q3 2026, an estimated $296.
Ligand Pharmaceuticals made up ﹤0.01% of Fortitude Family Office's portfolio in Q3 2026, its #2048 holding.
Fortitude Family Office first reported a position in Ligand Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
35 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.